STOCK TITAN

Vanguard reports 7.51% stake in Amgen (NASDAQ: AMGN) via Schedule 13G

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Amgen Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 40,510,484 shares of Amgen common stock, representing 7.51% of the class as of 03/31/2026. The filing shows 5,496,252 shares with sole voting power and 40,510,484 shares with sole dispositive power.

Positive

  • None.

Negative

  • None.

Insights

Large passive stake reported by Vanguard Capital Management.

Vanguard Capital Management reports beneficial ownership of 40,510,484 shares (7.51%) of Amgen common stock as of 03/31/2026. The filing attributes sole dispositive power over all reported shares and sole voting power over a subset (5,496,252 shares).

Because Schedule 13G typically reflects passive institutional holdings, this filing documents scale of ownership rather than an active control intent; subsequent filings or disclosures would be needed to signal changes in voting alignment or active engagement.

Reporting date 03/31/2026 Date tied to reported ownership
Beneficial ownership 40,510,484 shares Amount beneficially owned reported in Schedule 13G
Percent of class 7.51% Percent of Amgen common stock reported
Sole voting power 5,496,252 shares Shares with sole power to vote
Sole dispositive power 40,510,484 shares Shares with sole power to dispose
CUSIP 031162100 Amgen Inc common stock identifier
Schedule 13G regulatory
"Vanguard Capital Management reports beneficial ownership of 40,510,484 shares"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially owned financial
"Amount beneficially owned: 40510484 (b) Percent of class: 7.51 %"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 40510484"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Investment Company Act of 1940 regulatory
"investment companies registered under the Investment Company Act of 1940"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.





031162100

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Capital Management
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:04/29/2026

FAQ

What stake does Vanguard Capital Management report in AMGN?

Vanguard Capital Management reports beneficial ownership of 40,510,484 shares, equal to 7.51% of Amgen's common stock as of 03/31/2026. The filing lists sole dispositive power over all reported shares and sole voting power over 5,496,252 shares.

Does the Schedule 13G indicate Vanguard intends to control Amgen (AMGN)?

No. The Schedule 13G filing is used by passive institutional investors; it does not assert an active control intent. The filing documents beneficial ownership and voting/dispositive powers but does not state that Vanguard seeks to influence Amgen's control or management.

Which voting and disposition powers are reported by Vanguard for AMGN?

Vanguard reports 5,496,252 shares with sole voting power and 40,510,484 shares with sole dispositive power for AMGN. Shared voting and dispositive powers are reported as 0 in this filing as of the reporting date.

What date and CUSIP are tied to this AMGN beneficial ownership filing?

The filing is tied to the reporting date 03/31/2026 and references CUSIP 031162100 for Amgen Inc common stock. The Schedule 13G was signed on 04/29/2026 by a Vanguard officer.

Does the filing identify other persons with over 5% ownership of AMGN?

The filing states that no other single person's interest reported here exceeds 5%. It explains holdings include Vanguard funds and managed accounts under Vanguard Capital Management's dispositive authority, per the text of the Schedule 13G.